Eledon Pharmaceuticals, Inc. (ELDN) financial statements (2022 and earlier)

Company profile

Business Address 19900 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments84,83394,041101,133108,579114,195114,4648,764
Cash and cash equivalents84,83394,041101,133108,579114,195114,4648,764
Receivables  87197110214162
Prepaid expense1,4404097109581,198401535
Other current assets34111126381783
Other undisclosed current assets2,0391,097641481895217
Total current assets:88,34695,558102,582110,241115,630115,1019,761
Noncurrent Assets
Operating lease, right-of-use asset76822226792138183228
Property, plant and equipment      1
Intangible assets, net (including goodwill)48,64848,64848,64848,64848,64844,466 
Goodwill48,64848,64848,64848,64848,64844,466 
Other noncurrent assets400356422315383449511
Other undisclosed noncurrent assets32,38632,38632,38632,38632,38632,386 
Total noncurrent assets:82,20281,61281,72381,44181,55577,484740
TOTAL ASSETS:170,548177,170184,305191,682197,185192,58510,501
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,4742,6201,8242,6891,6191,549387
Accounts payable1,8131,5988571,5141,366758150
Accrued liabilities25091135211155686114
Employee-related liabilities1,41193183296498105123
Other undisclosed current liabilities9271,4268531,5178644,581710
Total current liabilities:4,4014,0462,6774,2062,4836,1301,097
Noncurrent Liabilities
Long-term debt and lease obligation4004590   48
Operating lease, liability4004590   48
Liabilities, other than long-term debt1,7522,3313,0173,6054,106  
Deferred income tax liabilities1,7522,3313,0173,6054,106  
Other undisclosed noncurrent liabilities      (48)
Total noncurrent liabilities:2,1522,3763,1073,6054,106 48
Total liabilities:6,5536,4225,7847,8116,5896,1301,145
Temporary equity, carrying amount     164,949 
Stockholders' equity
Stockholders' equity attributable to parent163,995170,748178,521183,871190,59621,5069,356
Common stock1414141415119
Additional paid in capital278,880276,827274,783272,749270,97495,99477,682
Accumulated deficit(114,899)(106,093)(96,276)(88,892)(80,393)(74,489)(68,345)
Total stockholders' equity:163,995170,748178,521183,871190,59621,5069,356
TOTAL LIABILITIES AND EQUITY:170,548177,170184,305191,682197,185192,58510,501

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(9,385)(10,506)(7,971)(9,005)(6,348)(6,148)(2,591)
Operating loss:(9,385)(10,506)(7,971)(9,005)(6,348)(6,148)(2,591)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 3(1)54045
Other undisclosed loss from continuing operations before equity method investments, income taxes    (4,829)  
Loss from continuing operations before income taxes:(9,385)(10,503)(7,972)(9,000)(11,137)(6,144)(2,586)
Income tax benefit579686588501   
Other undisclosed income from continuing operations    404  
Net loss:(8,806)(9,817)(7,384)(8,499)(10,733)(6,144)(2,586)
Other undisclosed net income attributable to parent    4,829  
Net loss available to common stockholders, diluted:(8,806)(9,817)(7,384)(8,499)(5,904)(6,144)(2,586)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(8,806)(9,817)(7,384)(8,499)(10,733)(6,144)(2,586)
Comprehensive loss, net of tax, attributable to parent:(8,806)(9,817)(7,384)(8,499)(10,733)(6,144)(2,586)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: